A new phenylacetate-bisphosphonate inhibits breast cancer cell growth by proapoptotic and antiangiogenic effects

Anticancer Research

Volumn 22, Issue 6 C, 2002, Pages 3925-3931

  Sebbah Louriki, Malika ^a   Colombo, Bruno M ^a   El Manouni, Driss ^a   Martin, Antoine ^b   Salzmann, Jean Loup ^a   Leroux, Yves ^a   Perret, Gérard Y ^a   Crépin, Michel ^a,c  

^a UNIVERSITÉ PARIS 13   (France)

^b AVICENNE HOSPITAL   (France)

^c Lab Endothelium et Angiogenese   (France)

Author keywords

Angiogenesis; Apoptosis; Breast cancer; Mice; Phenylacetate bisphosphonate

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; PHENYLACETATE BISPHOSPHONATE; PHENYLACETIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSTASIS; CYTOTOXICITY; DRUG EFFECT; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL DIVISION; DIPHOSPHONATES; FEMALE; HUMANS; MICE; MICE, NUDE; PHENYLACETATES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036875338     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Ferrandina G, Melichar B, Loercher A, Verschraegen CF, Kudelka AP, Edwards CL, Scambia G, Kavanagh JJ, Abbruzzese JL and Freedman RS: Growth inhibitory effects of sodium phenylacetate 9NSC 3039) on ovarian carcinoma cells in vitro. Cancer Res 57: 4309-4315, 1997.
2. Gore SD, Samid D and Weng LJ: Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells. Clin Cancer Res 3: 1755-1762, 1997.
3. Adam L, Crepin M, Savin C and Israel L: Sodium phenylacetate induces growth inhibition and Bcl-2 down-regulation and apoptosis in MCF7ras cells in vitro and in nude mice. Cancer Res 55: 5156-5160, 1995.
4. Thibault A, Samid D, Cooper MR, Figg WD, Tompkins AC, Patronas N, Headlee DJ, Kohler DR, Venzon DJ and Myers CE: Phase I study of phenylacetate administrered twice daily to patients with cancer. Cancer 75: 2932-2938, 1995.
5. Chang SM, Kuhn JG, Robins HI, Schold SC, Spence AM, Berger MS, Mehta MP, Bozik ME, Pollack I, Schiff D, Gilbert M, Rankin C and Prados MD: Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J Clin Oncol 17: 984-990, 1999.
6. Gibbs JB, Oliff A and Kohl NE: Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 77: 175-178, 1994.
7. Siris ES, Chines AA, Altman RD, Brown JP, Johnston CC Jr, Lang R, McClung MR, Mallette LE, Miller PD, Ryan WG, Singer FR, Tucci JR, Eusebio RA and Bekker PJ: Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study. J Bone Miner Res 13: 1032-1038, 1998.
8. Rosen CJ and Kessenich CR: Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone diseases. Drugs 51: 537-551, 1996.
9. Theriault RL and Hortobagyi GN: The evolving role of bisphosponates. Semin Oncol 28: 284-290, 2001.
10. Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD and Clezardin P: Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular martices. Cancer Res 57: 3890-3894, 1997.
11. Senaratne SG and Colston KW: Direct effects of bisphosphonates on breast cancer cells. Breast Cancer Res 4: 18-23, 2002.
12. Senaratne SG, Mansi JL and Colston KW: The bisphosphonate zoledronic acid impairs membrane localisation and induces cytochrome c release in breast cancer cells. Br J Cancer 86: 1479-1486, 2002.
13. Thibout D, Benedetto M, Kraemer M, Sainte-Catherine O, Dervin C and Crépin M: Sodium phenylacetate modulates the synthesis of autocrine and paracrine growth factors secreted by breast cancer cel lines. Anticancer Res 18: 2657-2661, 1998.
14. Di Benedetto M, Starzec A, Colombo BM, Briane D, Perret GY, Kraemer M and Crépin M: Aponecrotic, antiagiogenic and antiproliferative effects of a novel dextran derivative on breast cancer growth in vivo and in vitro. Br J Pharmacol 135: 1859-1871, 2002.
15. Leers MP, Kolgen W, Bjorklund V, Bergman T, Tribbick G, Persson B, Bjorklund P, Ramaekers FC, Bjorklund B, Nap M, Jornval H and Schutte B: Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 187: 567-572, 1999.
16. Dickson RB, Kasid A, Huff KK, Bates SE, Knabbe C, Bronzert D, Gelmann EP and Lippman ME: Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17 beta-estradiol or v-Ha-ras oncogene. Proc Natl Acad Sci USA 84: 837-841, 1987.
17. Thibout D, Kraemer M, Di Benedetto M, Saffar L, Gattegno L, Derbin C and Crepin M: Sodium phenylacetate (NaPa) induces modifications of the proliferation, the adhesion and the cell cycle of tumoral epithelial breast cells. Anticancer Res 19: 2121-2126, 1999.
18. Shack S, Chen LC, Miller AC, Danesi R and Samid D: Increased susceptibility of ras-transformed cells to phenylacetate is associated with inhibition of p21ras isoprenylation and phenotypic reversion. Int J Cancer 63: 124-129, 1995.
19. Luckman SP, Hughes DE, Coxon FR, Grahan R, Russell G and Rogers MJ: Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binging proteins, including Ras. J Bone Miner Res 13: 581-589, 1998.
20. Hughes DE, MacDonald BR, Russell RG and Gowen M: Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 83: 1930-1935, 1989.
21. Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN and Spelsberg TC: Biophosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 60: 6001-6007, 2000.
22. Senaratne SG, Pirianov G, Mansi JL, Arnett TR and Colston KW: Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82: 1459-1468, 2000.
23. Lee MV, Fong EM, Singer FFR and Guenette RS: Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 61: 262-2608, 2001.